- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 199 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.11.25 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11.25 | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10.25 | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09.25 | Summers Value Partners' Update on Journey Medical (DERM) | 6 | Insider Monkey | ||
| 28.08.25 | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 25.08.25 | H.C. Wainwright stuft Journey Medical mit "Kaufen" ein - Rosacea-Medikament Emrosi als entscheidender Faktor | 9 | Investing.com Deutsch | ||
| 25.08.25 | H.C. Wainwright initiates Journey Medical stock with Buy rating on Emrosi potential | 2 | Investing.com | ||
| 20.08.25 | Journey Medical setzt auf Rosacea-Mittel Imrozi für Profitabilitätswende | 5 | Investing.com Deutsch | ||
| 13.08.25 | Journey Medical targets sustained EMROSI momentum and profitability through 2025 as prescriber base nearly triples | 5 | Seeking Alpha | ||
| 12.08.25 | Journey Medical Corp - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 12.08.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 586 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,295 | -0,07 % | Pfizer-Aktie: Langsam, aber stetig! | Die Pfizer-Aktie hat sich seit dem Spätherbst spürbar erholt und sendet neue technische wie fundamentale Signale an den Markt. Vor dem Hintergrund wichtiger Studiendaten, regulatorischer Entscheidungen... ► Artikel lesen | |
| GILEAD SCIENCES | 120,10 | +0,25 % | Leerink Partners raises Gilead Sciences stock price target to $146 on HIV pipeline | ||
| ELI LILLY | 874,00 | -0,15 % | Roche-Aktie: Kampf gegen Eli Lilly und Novo Nordisk | In den vergangenen zehn Jahren tat sich die Roche-Aktie nicht durch eine besonders gute Kursentwicklung hervor. Doch in den letzten drei Monaten legte der Kurs des Schweizer Pharmariesen um über +25%... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 397,55 | +0,25 % | Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals | ||
| EYEPOINT | 11,370 | -0,35 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 | - Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 160,00 | -1,23 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 136,55 | -1,34 % | Boehringer Ingelheim Limited: Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer | Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients
Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic... ► Artikel lesen | |
| OPKO HEALTH | 1,057 | -0,94 % | OPKO Health, Inc.: OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results | MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights... ► Artikel lesen | |
| UNITED THERAPEUTICS | 388,60 | -0,82 % | United Therapeutics reports positive phase 1 results for bioengineered liver | ||
| ROYALTY PHARMA | 34,990 | -0,48 % | Royalty Pharma: UBS stuft Aktie auf "Kaufen" hoch und verweist auf starkes Wachstumsprofil | ||
| CATALYST PHARMACEUTICALS | 20,200 | -1,51 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,92 | -0,46 % | Barclays startet Coverage für BridgeBio Pharma mit "Overweight"-Rating | ||
| TG THERAPEUTICS | 24,865 | +0,12 % | TG Therapeutics stellt neue Daten zu MS-Medikament BRIUMVI auf Fachkongress vor | ||
| AVADEL PHARMACEUTICALS | 17,900 | -0,56 % | Alkermes stock price target raised to $47 from $46 at UBS on Avadel deal | ||
| CORBUS PHARMACEUTICALS | 7,050 | +1,44 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -1,07 % bei einem Aktienkurs von 8,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.